AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06646328
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-fractional heparin will be used in one arm with an initial dose of 500-1000 IU/hour with adaptation of the infusion to the patient and the clotting time.
Trial: NCT02093325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
Trial: NCT04000698
Drug: Preparative regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparative chemotherapy before allogeneic HSCT~* Fludarabin~* Cytarabine~* Venetoclax~* Daratumomab~* Vecanoid Condition~* treosulfan~* fludarabine~* thiophosphomide~* Venetoclax~* Plerixafor GVHD prophylaxis~* abatacept~* tocilizumab~* rituximab~* HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes
Trial: NCT05871398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02985983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Placebo by subcutaneous (SC) injection until week 16. Administered Brodalumab by SC injection from week 17 until week 66.
Trial: NCT03164473
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablets : 2 mg/kg/day for 24 months
Trial: NCT03164473
Drug: Placebo-azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablets for 24 months
Trial: NCT02559791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo once monthly for 2 months
Trial: NCT00882856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04599933
Drug: CSF-1
RxNorm normalized name: CSF-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop bilaterally twice daily for approximately 2 weeks.
Trial: NCT04599933
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop bilaterally twice daily for approximately 2 weeks.
Trial: NCT01424046
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
Trial: NCT01297088
Drug: BAY86-9596
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single dose administration of a diagnostic agent
Trial: NCT01652014
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV over 1 hour on Day -6; after pre-hydration
Trial: NCT01021761
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Trial: NCT01021761
Drug: nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Trial: NCT00614120
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride placebo, capsules
Trial: NCT00614120
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo, s.c. (under the skin) injection
Trial: NCT00003913
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01775358
Drug: ALRN-5281 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01775358
Drug: Placebo 0.015 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01775358
Drug: Placebo 0.15mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01670799
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
Trial: NCT01409772
Drug: Ethanol Lock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol Lock
Trial: NCT00268333
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00268333
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01869699
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 1 gram/100mLs intravenously administered over 15 minutes
Trial: NCT01869699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
Trial: NCT00623714
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
Trial: NCT01542502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily subcutaneous injection
Trial: NCT01314482
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg bd for 3 days before surgery
Trial: NCT02935894
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg ibuprofen given to inhibit cyclooxygenase metabolism
Trial: NCT03824743
Drug: Lactate Ringer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients managed with Lactate Ringer and obstetric hemorrhage
Trial: NCT03824743
Drug: Plasma-lyte
RxNorm normalized name: Plasma-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients managed with Plasma-Lyte and obstetric hemorrhage
Trial: NCT01848132
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide: intravenous, 750 mg/m2, day 1
Trial: NCT01848132
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin:intravenous, 50 mg/m2, day 1
Trial: NCT01499251
Drug: Ancillary Study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
Trial: NCT00488969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02284568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02284568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT04336449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - single intravenous infusion
Trial: NCT03731559
Drug: DTG 50 mg OD with food
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg once daily with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy
Trial: NCT03731559
Drug: DTG 50 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
Trial: NCT03219359
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ \>20x104/ml then leukapheresis daily to collection goal
Trial: NCT03219359
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day -6 to -3: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)
Trial: NCT02644980
Drug: Maintenance of anesthesia
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
Trial: NCT00509756
Drug: FXR-450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, single oral doses from 10 mg to 450 mg
Trial: NCT00509756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule similar to active drug
Trial: NCT00655733
Drug: HMPL-004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-004 1200 mg/d
Trial: NCT00655733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1200 mg/d
Trial: NCT01701193
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01867294
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01867294
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given topically
Trial: NCT01867294
Drug: Therapeutic Hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given topically
Trial: NCT01576276
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 administrations of ketorolac over course of study
Trial: NCT01993589
Drug: comparison of pain relievers
RxNorm normalized name: LidoPro Pain Relieving Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01993589
Drug: comparison of pain relievers during curattage
RxNorm normalized name: LidoPro Pain Relieving Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02720744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01619644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with an oral dosage of 30 mg/kg/jour
Trial: NCT01381419
Drug: GSK1144814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose.
Trial: NCT01381419
Drug: GSK1144814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
Trial: NCT01011166
Drug: IDX184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
Trial: NCT01011166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
Trial: NCT01945801
Drug: Lasilactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug (spironolactone 100 mg plus furosemide 20 mg).
Trial: NCT01945801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.
Trial: NCT01381419
Drug: GSK1144814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
Trial: NCT00799643
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salsalate 3.5 g/d orally, divided dosing
Trial: NCT00799643
Drug: Salsalate Placebo
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02181322
Drug: Meloxicam - low dose
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02181322
Drug: Meloxicam - medium dose
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02181322
Drug: Meloxicam - high dose
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00245297
Drug: Kogenate FS, reconstituted in a suspension of liposomes
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02236806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily
Trial: NCT01520142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
Trial: NCT03179293
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be administered manually over the next 3 min prior to the patient leaving the OR
Trial: NCT03558490
Drug: Investigator's choice of anti-cancer treatment (except immunotherapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All anti-cancer treatments (except immunotherapy) will be left to the free choice of investigators. Participants shall be prescribed by the healthcare team both of the following symptomatic treatments: loperamide or any other anti-diarrheic treatment in case of diarrhea; and a prescription for any medication indicated in case of nausea/vomiting. A written prescription will be made by the investigator at screening for loperamide or any other anti-diarrheic treatment and symptomatic treatment for nausea/vomiting with documented dosage and duration.
Trial: NCT00720343
Drug: Choline
RxNorm normalized name: Choline
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Choline 20 grams before surgery
Trial: NCT00720343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin Capsule
Trial: NCT01963845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03229291
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same formulation as topical SM04755 solution, without SM04755 included.
Trial: NCT04371445
Drug: Prednisolone Acetate 1% Oph Susp
RxNorm normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.
Trial: NCT03823703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT00162006
Drug: Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01970878
Drug: GP MDI (PT001)
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI administered as two puffs BID
Trial: NCT01386632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
Trial: NCT00443820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo) once daily for 48 weeks
Trial: NCT00443820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo) once daily for 24 weeks
Trial: NCT03493282
Drug: Active Treatment- CT1812 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT1812
Trial: NCT03493282
Drug: Active Treatment- CT1812 300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT1812
Trial: NCT03493282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT01366976
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1g every 6 hours for 4 doses over 24 hours
Trial: NCT01377844
Drug: EGT0001442
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01377844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02447497
Drug: 3M CHG/IPA Surgical Skin Preparation - Inguinal Region
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
Trial: NCT00027924
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01889173
Drug: TNX-102-B SL Tablets at 2.8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
Trial: NCT01059643
Drug: LY2523355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.
Trial: NCT00246337
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match assigned treatment arm; one orally-administered dose
Trial: NCT00246337
Drug: MK0974
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0974 50 mg; one orally-administered dose
Trial: NCT00246337
Drug: MK0974
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0974 100 mg; one orally-administered dose
Trial: NCT00246337
Drug: MK0974
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0974 200 mg; one orally-administered dose
Trial: NCT03185143
Drug: Naltrexone and Acetaminophen Combination
RxNorm normalized name: bupropion and naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat a single Qualified Migraine attack.
Trial: NCT03185143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
Trial: NCT01209156
Drug: [18F] PBR111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of \[18F\]PBR111, followed by PET imaging.
Trial: NCT00176644
Drug: Transdermal Estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.~The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed.
Trial: NCT00246337
Drug: MK0974
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0974 300 mg; one orally-administered dose
Trial: NCT00246337
Drug: MK0974
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0974 400 mg; one orally-administered dose
Trial: NCT00246337
Drug: MK0974
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0974 600 mg; one orally-administered dose
Trial: NCT00653185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Trial: NCT01686152
Drug: Zyclara®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00311519
Drug: Hylenex
RxNorm normalized name: Hylenex
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02004899
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
Trial: NCT01226511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02174913
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 1-2 mcg/kg iv for induction and then 0.5-1.0 mcg/kg/hr infusion is used for analgesic.
Trial: NCT03381404
Drug: [14C] MT-8554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-C MT-8554